Intravitreal Tissue Plasminogen Activator Injection for Treatment-Resistant Diabetic Macular Edema of the Vitrectomized Eye

Código QR

Intravitreal Tissue Plasminogen Activator Injection for Treatment-Resistant Diabetic Macular Edema of the Vitrectomized Eye

Diabetic macular edema (DME) is the main cause of visual loss in patients with diabetic retinopathy. DME has been treated using intravitreal anti-vascular endothelial growth factor (VEGF) drugs, steroids, laser photocoagulation, vitreoretinal surgery, and their combinations. These modalities are gen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ren Aoki, Makoto Hatano, Fumiaki Higashijima, Takuya Yoshimoto, Masanori Mikuni, Tadahiko Ogata, Yuka Kobayashi, Makiko Wakuta, Kazuhiro Kimura
Formato:	article
Lenguaje:	EN
Publicado:	Karger Publishers 2021
Materias:	tissue plasminogen activator diabetic macular edema vitrectomized eye central retinal thickness visual acuity Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/a7bc3bcbc55f46a5a30e91fc8cfbb2e9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion
por: Kumagai K, et al.
Publicado: (2019)

Choroidal Blood Flow After Intravitreal Ranibizumab in Vitrectomized and Non-Vitrectomized Eyes with Diabetic Macular Edema
por: Pessoa B, et al.
Publicado: (2021)

Pars Planectomy: Preliminary Report of a New Glaucoma Filtering Technique in Vitrectomized Eyes
por: Wangsupadilok B, et al.
Publicado: (2021)

One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
por: Tran THC, et al.
Publicado: (2021)

Clinical Outcome and Drug Expenses of Intravitreal Therapy for Diabetic Macular Edema: A Retrospective Study in Sardinia, Italy
por: Chiara Altana, et al.
Publicado: (2021)

Baseline Subfoveal Choroidal Thickness as a Predictor for Response to Short-Term Intravitreal Bevacizumab Injections in Diabetic Macular Edema
por: Dweikat A, et al.
Publicado: (2021)

Multicenter, Prospective, Randomized Study of Dexamethasone Intravitreal Implant in Patients with Center-Involved Diabetic Macular Edema in the Asia-Pacific Region
por: Wei W, et al.
Publicado: (2021)

Effectiveness of 190 μg Fluocinolone Acetonide and 700 μg Dexamethasone Intravitreal Implants in Diabetic Macular Edema Using the Area-Under-the-Curve Method: The CONSTANT Analysis
por: Zarranz-Ventura J, et al.
Publicado: (2020)

PLASMINOGEN ACTIVATOR OF YERSINIA PESTIS
por: V. V. Evseeva, et al.
Publicado: (2015)

Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes
por: Coelho J, et al.
Publicado: (2019)

Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice
por: Campos Polo R, et al.
Publicado: (2018)

Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab
por: Nixon DR, et al.
Publicado: (2018)

Comment on ’Effectiveness of 190 μg Fluocinolone Acetonide versus 700 μg Dexamethasone Intravitreal Implants in Diabetic Macular Edema Using the Area-Under-the-Curve Method: The CONSTANT Analysis’ [Response to Letter]
por: Zarranz-Ventura J, et al.
Publicado: (2020)

Tissue plasminogen activator versus heparin for locking dialysis catheters: A systematic review
por: Belal M Firwana, et al.
Publicado: (2011)

Impact of Different Clinical Baseline Characteristics on Intravitreal Dexamethasone Implant Ozurdex® Outcomes
por: Udaondo P, et al.
Publicado: (2021)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
por: Fouda SM, et al.
Publicado: (2017)

Real-World Outcomes in Patients with Diabetic Macular Edema Treated Long Term with Ranibizumab (VISION Study)
por: Van Aken E, et al.
Publicado: (2020)

Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema
por: Thomas BJ, et al.
Publicado: (2016)

Inhibition of epithelial–mesenchymal transition in retinal pigment epithelial cells by a retinoic acid receptor-α agonist
por: Yuka Kobayashi, et al.
Publicado: (2021)

Effect of Tissue Plasminogen Activator on Treatment Outcome and Neuronal Degeneration in Acute Ischemic Stroke
por: Muhammad Masoud, et al.
Publicado: (2021)

Benzalkonium chloride-induced myofibroblastic transdifferentiation of Tenon’s capsule fibroblasts is inhibited by coculture with corneal epithelial cells or by interleukin-10
por: Chiemi Yamashiro, et al.
Publicado: (2021)

Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
por: Paulose R, et al.
Publicado: (2016)

Intravitreal bevacizumab injections for diabetic macular edema – predictors of response: a retrospective study
por: Joshi L, et al.
Publicado: (2016)

Edema hemorrágico agudo del lactante: reporte de un caso de presentación atípica
por: Yarmuch G,Paula, et al.
Publicado: (2012)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
por: Pessoa B, et al.
Publicado: (2021)

Intravitreal pegaptanib for the treatment of ischemic diabetic macular edema
por: Kiire CA, et al.
Publicado: (2015)

Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials
por: Dugel PU, et al.
Publicado: (2016)

Complement C4-A and Plasminogen as Potential Biomarkers for Prediction of Papillary Thyroid Carcinoma
por: Yichao Wang, et al.
Publicado: (2021)

Edema fisiológico del recién nacido
por: ORTEGA,RAUL, et al.
Publicado: (1947)

The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions
por: Ivanovska Adjievska B, et al.
Publicado: (2017)

Effectiveness and Safety of the Clareon Monofocal Intraocular Lens: Outcomes from a 12-Month Single-Arm Clinical Study in a Large Sample
por: Lehmann R, et al.
Publicado: (2021)

A Randomized, Controlled, Prospective Study of the Effectiveness and Safety of an Intracanalicular Dexamethasone Ophthalmic Insert (0.4 Mg) for the Treatment of Post-Operative Inflammation in Patients Undergoing Refractive Lens Exchange (RLE)
por: Larsen J, et al.
Publicado: (2021)

EFFECT OF INTRAVITREAL TRIAMCINOLONE ACETONIDE IN REFRACTORY DIABETIC MACULAR EDEMA
por: Ume Sughra, et al.
Publicado: (2021)

Treatment of refractory uveitic macular edema: results of a first and second implant of long-acting intravitreal dexamethasone
por: Zola M, et al.
Publicado: (2017)

Intravitreal Aflibercept versus Laser Photocoagulation in Asian Patients with Diabetic Macular Edema: The VIVID-East Study
por: Chen YX, et al.
Publicado: (2020)

Experiencia de trombolisis sistematizada en infarto cerebral agudo en un hospital público de Chile
por: Figueroa-Reyes,Tatiana, et al.
Publicado: (2011)

Clinical therapeutic effects of intravitreal injection of Conbercept for macular edema in different types of retinal vein occlusion
por: Peng-Yao Lin, et al.
Publicado: (2021)

Subretinal Injection of Recombinant Tissue Plasminogen Activator and Gas Tamponade to Displace Acute Submacular Haemorrhages Secondary to Age-Related Macular Degeneration
por: Iannetta D, et al.
Publicado: (2021)

Edema pulmonar de gran altura
por: UNDURRAGA M,FELIPE, et al.
Publicado: (2003)

Evaluation Of The Timing Of Intravitreal Bevacizumab Injection As Adjuvant Therapy To Panretinal Photocoagulation In Patients With Diabetic Macular Edema Secondary To Diabetic Retinopathy
por: Kartasasmita A, et al.
Publicado: (2019)